NFKB1 and colitis: In conclusion, these results support the hypothesis that oral administration of taxifolin can protect against mice colitis through alleviating mucosa damage and inflammatory responses, inhibiting NF-κB signaling, improving TJ barrier function, and normalizing the gut microbiota.